Dryja-Brodowska Anna, Obrzut Bogdan, Obrzut Maciej, Darmochwał-Kolarz Dorota
Department of Obstetrics & Gynecology, Faculty of Medicine, University of Rzeszow, Rejtana 16C, 35-959 Rzeszow, Poland.
Faculty of Medicine, University of Zielona Góra, Licealna Str 9, 65-417 Zielona Góra, Poland.
J Clin Med. 2025 Jul 8;14(14):4849. doi: 10.3390/jcm14144849.
Endometriosis is a complex, estrogen-dependent condition that can significantly impact women's quality of life and fertility. Current diagnostic strategies remain invasive and often prolonged, demonstrating the need for reliable, non-invasive biomarkers. In this context, microRNAs (miRNAs), due to their stability in blood and regulatory roles in inflammation and cell proliferation, have emerged as promising candidates. This review systematically analyzes 17 studies published between 2010 and 2025 that investigated the diagnostic utility of circulating and tissue-based miRNAs in endometriosis. A wide range of dysregulated miRNAs was identified, with miR-125b-5p, miR-451a, and miR-3613-5p showing the most consistent alterations across studies. However, diagnostic performance varied considerably-largely due to methodological heterogeneity. Key differences were observed in sample type (serum, plasma, endometrium), patient selection, and control group definition. The menstrual cycle phase and hormonal status were often not matched or reported, limiting reproducibility. Despite encouraging findings, the current evidence base is weakened by inconsistent protocols and limited validation. Standardized, multicenter research with well-characterized patient cohorts is essential to the establishment of clinically applicable miRNA-based diagnostics. If validated, miRNAs may offer a transformative, non-invasive approach for earlier detection and improved management of endometriosis.
子宫内膜异位症是一种复杂的、雌激素依赖性疾病,会对女性的生活质量和生育能力产生重大影响。目前的诊断策略仍然具有侵入性,而且往往耗时较长,这表明需要可靠的非侵入性生物标志物。在这种背景下,微小RNA(miRNA)因其在血液中的稳定性以及在炎症和细胞增殖中的调节作用,已成为有前景的候选标志物。本综述系统分析了2010年至2025年间发表的17项研究,这些研究调查了循环miRNA和组织miRNA在子宫内膜异位症中的诊断效用。研究发现了多种失调的miRNA,其中miR-125b-5p、miR-451a和miR-3613-5p在各项研究中显示出最一致的变化。然而,诊断性能差异很大,这主要是由于方法学上的异质性。在样本类型(血清、血浆、子宫内膜)、患者选择和对照组定义方面观察到了关键差异。月经周期阶段和激素状态往往不匹配或未报告,这限制了可重复性。尽管有令人鼓舞的发现,但目前的证据基础因方案不一致和验证有限而受到削弱。开展标准化、多中心研究,纳入特征明确的患者队列,对于建立基于miRNA的临床适用诊断方法至关重要。如果得到验证,miRNA可能为子宫内膜异位症的早期检测和改善管理提供一种变革性的非侵入性方法。